TY - CHAP M1 - Book, Section TI - Small Cell Carcinoma of the Lung A1 - Cascone, Tina A1 - Gold, Kathryn A. A1 - Glisson, Bonnie S. A2 - Kantarjian, Hagop M. A2 - Wolff, Robert A. PY - 2016 T2 - The MD Anderson Manual of Medical Oncology, 3e AB - Small cell lung cancer (SCLC) is an aggressive bronchogenic carcinoma diagnosed in 14% of all patients with lung cancer, accounting for approximately 30,000 new cases annually in the United States (1). It is distinguished from non–small cell lung cancer (NSCLC) by its rapid doubling time, high proliferative fraction, and early development of metastases. Regional lymph node involvement or distant metastasis is present in 90% or more of patients at diagnosis. Historically, SCLC has been staged as limited disease (LD), which is confined to the ipsilateral thorax of origin and regional nodes, versus extensive disease (ED). The recent International Association for the Study of Lung Cancer (IASLC) staging project and American Joint Committee on Cancer/International Union Against Cancer (AJCC/UICC) seventh edition suggest use of the tumor, node, metastasis (TNM) system for the staging of SCLC (2). Clinically, the limited- and extensive-stage classification is practical given that most patients present with advanced disease (stages III-IV) and are only rarely candidates for resection. SN - PB - McGraw-Hill Medical CY - New York, NY Y2 - 2024/03/28 UR - accessmedicine.mhmedical.com/content.aspx?aid=1126741555 ER -